IDH2 and central nervous system cancer: Interestingly, in the case of IDH-mutant gliomas, an opposite trend is seen, wherein a high APP score is seen in HMP gliomas, suggesting a potential value in considering IDH-mutant HMP gliomas for immunotherapy rather than their NHMP counterparts (Figure 4).